ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cathay Industrial Biotech, a Chinese company that produces chemicals by fermentation, has dropped plans to list its stock in the U.S. by means of American Depositary Shares. HBM BioVentures, a Swiss private equity fund that invested $28 million in Cathay, says Cathay decided to halt the listing process because of poor conditions in global stock markets. In 2010, Cathay recorded a loss of $2 million on sales of $125 million. The company produces diacids by biocatalysis for clients including DuPont and AkzoNobel. It also makes biobutanol.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter